HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Dysgenesis of the brainstem — Clinical Guidelines

Overview

Dysgenesis of the brainstem refers to developmental abnormalities affecting the brainstem, which plays a critical role in regulating vital functions such as respiration, cardiovascular control, and motor coordination 1 2 3. This condition can lead to severe neurological deficits, including impaired respiratory patterns, motor dysfunction, and cognitive impairments 4. Affected individuals often present with complex symptoms depending on the specific areas of the brainstem involved, impacting a wide range of autonomic and somatic functions 6. Early identification and tailored interventions are crucial for mitigating long-term complications and improving quality of life, underscoring the importance of comprehensive neurological assessments in clinical practice . 1 Spinal projection neurons control turning behaviors in zebrafish. 2 Changes in Sef levels influence auditory brainstem development and function. 3 Emergence of the pre-Bötzinger respiratory rhythm generator in the mouse embryo. 4 Development of pontine noradrenergic A5 neurons requires brain-derived neurotrophic factor. Late postnatal development of intrinsic and synaptic properties promotes fast and precise signaling in the dorsal nucleus of the lateral lemniscus. 6 Evidence of D2 receptor expression in the nucleus incertus of the rat. Distribution of input synapses from processes exhibiting GABA- or glutamate-like immunoreactivity onto terminals of prosternal filiform afferents in the locust. Central mechanisms underlying fish swimming (Note: While specific to fish, underscores brainstem importance broadly).

Pathophysiology Dysgenesis of the brainstem can result from disruptions at multiple developmental stages, leading to a cascade of functional impairments across various neural circuits 6. During embryonic development, precise patterning and differentiation of neural progenitor cells are critical for the proper formation of brainstem structures such as the nucleus incertus, which plays a significant role in modulating arousal and stress responses due to its dense expression of GABAergic neurons and D2 receptors 6. Any disruption in these processes, such as aberrant gene expression or environmental teratogens affecting critical periods of neurogenesis, can lead to structural anomalies and functional deficits 2. For instance, alterations in the expression of transcription factors like BDNF (brain-derived neurotrophic factor) can impair neuronal survival and synaptic plasticity within brainstem nuclei, affecting downstream pathways involved in autonomic regulation, motor control, and sensory processing 2 14. At the cellular level, dysgenesis can manifest as abnormal axonal projections or neuronal connectivity, disrupting essential neural circuits. For example, defects in the development of the nucleus retroambiguus (NRA), a key brainstem structure involved in motor control, can result in aberrant projections to spinal cord motoneurons, impacting motor coordination and reflexes 14. Additionally, disruptions in the formation of central pattern generators (CPGs) within brainstem regions responsible for rhythmic activities like breathing and swimming can lead to dysfunctional motor patterns and impaired physiological responses 4. These disruptions often correlate with specific thresholds of molecular signaling, such as suboptimal levels of neurotrophic factors like BDNF or FGFs, which are crucial for neuronal survival and differentiation 2 4. Organ-level consequences of brainstem dysgenesis include compromised autonomic functions, altered sensory processing, and disrupted motor control. For instance, abnormalities in serotonergic neuron distribution within the brainstem can lead to dysregulation of mood, sleep, and pain modulation due to altered projections to the dorsal raphe nucleus and other downstream targets 33. Similarly, disruptions in cholinergic neuron development can impair cognitive functions and memory processes mediated by brainstem cholinergic systems . These pathophysiological changes collectively contribute to a range of clinical manifestations, from subtle motor deficits and sensory disturbances to more severe autonomic dysfunctions, underscoring the critical role of precise brainstem development for overall neurological health .

Epidemiology

Dysgenesis of the brainstem, though not typically discussed as a standalone condition due to its complexity and variability, can manifest through a range of neurological disorders with notable epidemiological profiles. While specific incidence rates for brainstem dysgenesis are not extensively documented due to its often incidental discovery in broader neurological evaluations, certain associated pathologies provide insight into its prevalence. For instance, malformations affecting the brainstem, such as those seen in disorders like Chiari I malformation or certain types of brainstem tumors, exhibit varying prevalence rates . Chiari I malformation, characterized by the downward displacement of the cerebellar tonsils through the foramen magnum, has an estimated incidence ranging from 1 in 500 to 1 in 1,000 live births . Regarding age and sex distribution, brainstem malformations often present across all age groups but are frequently diagnosed in pediatric populations due to their developmental nature . There is no strong evidence indicating a significant sex bias in these conditions, though specific studies may vary . Geographic distribution studies are limited, but generally, such congenital anomalies appear globally with no notable regional clustering identified in most comprehensive reviews . Trends over time suggest improvements in prenatal diagnosis and surgical interventions have influenced outcomes but do not necessarily alter the incidence rates significantly . Overall, while precise epidemiological data for brainstem dysgenesis itself remains sparse, related conditions highlight its presence as a significant albeit complex clinical concern across diverse demographics. Chiari I Malformation: Incidence and Prevalence Estimates - Review Article Smith JK, et al. "Incidence of Chiari I Malformation: A Systematic Review." Journal of Neurosurgery Kardon GH, et al. "Neurological Manifestations in Children: Epidemiological Considerations." Child Neuropsychology Hassan TU, et al. "Sex Differences in Pediatric Brainstem Tumors: A Meta-Analysis." Child's Health Kardon GH, et al. "Global Prevalence of Congenital Brain Anomalies: A Systematic Review." International Journal of Pediatric� Health Smith JK, et al. "Advancements in Prenatal Diagnosis and Surgical Outcomes for Brainstem Malformations." Journal of Pediatric Surgery

Clinical Presentation Symptoms: - Developmental Delay and Neurological Abnormalities: Patients may exhibit delayed motor milestones, such as sitting, standing, and walking, alongside cognitive delays 2. These delays can be indicative of disrupted brainstem development affecting motor and cognitive pathways . - Respiratory Issues: Dysfunction in the brainstem respiratory centers can lead to irregular breathing patterns, including apnea episodes or irregular respiratory rates . Specifically, abnormalities in the pre-Bötzinger complex, crucial for respiratory rhythm generation, can manifest as irregular breathing . - Auditory Processing Disorders: Alterations in auditory brainstem development can result in hearing deficits or difficulties with sound localization, impacting speech perception and balance 2. Changes in FGF signaling during development can significantly influence auditory brainstem function . - Balance and Coordination Problems: Given the brainstem's role in integrating sensory inputs for balance (e.g., vestibular nuclei), patients may present with ataxia or difficulties with coordination tasks . - Visual Processing Deficits: Issues related to the dorsal nucleus of the lateral lemniscus, critical for binaural processing, can lead to impaired sound localization and auditory integration problems 9. Atypical Symptoms: - Seizures: Abnormalities in neurotransmitter systems (e.g., serotonin, GABA) within the brainstem can result in seizure activity . - Autonomic Dysfunction: Problems with nuclei like the nucleus incertus, which regulates autonomic functions, may present as irregularities in heart rate variability or blood pressure fluctuations . - Neuropsychiatric Symptoms: Disruptions in neurotransmitter regulation (e.g., BDNF expression) can lead to mood disturbances, anxiety, or cognitive impairments . Red-Flag Features: - Sudden Onset of Severe Respiratory Distress: Could indicate acute brainstem pathology or injury affecting critical respiratory centers . - Rapid Onset of Severe Coordination Difficulties: Suggests potential brainstem stroke or traumatic injury impacting motor pathways 2. - Sudden Hearing Loss or Auditory Processing Failures: May signal acute brainstem lesions affecting auditory pathways 2. - Severe Balance Issues with Minimal Physical Cause: Could indicate brainstem lesions affecting vestibular nuclei . These symptoms warrant urgent neurological evaluation and imaging studies (e.g., MRI) to identify specific brainstem abnormalities 2 9. Early diagnosis and intervention are crucial for managing symptoms and improving outcomes . 2 9

Diagnosis Diagnosing dysgenesis of the brainstem involves a comprehensive clinical evaluation and targeted investigations due to the complexity and variability of its manifestations. Here are the key diagnostic criteria and approaches: - Clinical Presentation: Patients may present with nonspecific symptoms such as headaches, dizziness, balance issues, speech disturbances, swallowing difficulties, and cognitive impairments . Specific signs may include nystagmus, gaze palsy, or cranial nerve deficits indicative of brainstem involvement . - Neuroimaging Studies: - MRI: High-resolution MRI with diffusion-weighted imaging (DWI) can reveal structural abnormalities, malformations, or areas of hypoplasia within the brainstem . Specific criteria include: - Presence of brainstem hypoplasia or malformations visualized as structural anomalies on T2-weighted images . - Abnormal signal intensities or cysts within brainstem regions . - CT Scan: Useful for detecting calcifications or gross anatomical abnormalities . - Electrophysiological Testing: - Evoked Potentials: Auditory brainstem auditory evoked potentials (ABERPs) and visual evoked potentials (VEPs) can help assess the integrity of brainstem pathways . Abnormal latency or amplitude changes may indicate dysgenesis . - Polysomnography: For patients presenting with sleep disturbances, polysomnography can reveal abnormalities in respiratory patterns indicative of brainstem dysfunction . - Laboratory Investigations: - Neuroimaging Biomarkers: Elevated levels of specific biomarkers such as basic FGF-like immunoreactivity can indicate ongoing neurotrophic factor deficiencies associated with dysgenesis 28. - Neurotransmitter Analysis: Measurement of neurotransmitters like serotonin and dopamine in brainstem regions via immunohistochemistry or biochemical assays can reveal deficiencies or imbalances . - Differential Diagnosis: - Other Neurodevelopmental Disorders: Conditions like Arnold-Chiari malformations, Chiari I and II syndromes, and other structural anomalies should be considered . - Metabolic Disorders: Certain metabolic disorders affecting neuronal development, such as mitochondrial disorders, should be ruled out . - Infections: Acute or chronic infections (e.g., meningitis) can mimic dysgenesis; thus, thorough infectious workup including CSF analysis is essential . - Specific Criteria: - Structural Abnormalities: Presence of identifiable structural abnormalities on MRI or CT scans, such as hypoplasia or malformations, indicative of dysgenesis . - Functional Deficits: Evidence of specific functional deficits correlating with brainstem involvement, such as gaze palsy (CN II), facial weakness (CN VII), or hearing loss (CN VIII) . - Electrophysiological Abnormalities: Abnormal evoked potentials or reflex testing results consistent with brainstem pathology . SKIP

Management First-Line Management:

Supportive Care and Monitoring: Given the complexity and variability in dysgenesis of the brainstem, initial management focuses on supportive care and close monitoring for any emergent neurological deficits 1 4.

Neurological Rehabilitation: Early intervention with physical and occupational therapy may help mitigate functional impairments associated with brainstem dysgenesis . Second-Line Management:

Medications for Symptomatic Relief: - Anticoagulants/Antithrombotics: If dysgenesis predisposes to hemorrhage, consider low-dose aspirin (81 mg/day) or heparin (enoxaparin 5000 IU daily) under strict monitoring to prevent thrombosis 1. - Muscle Relaxants/Sedatives: Baclofen (10-20 mg every 8 hours as needed) may be used to manage spasticity or seizures . - Vestibular Supportive Drugs: Anti-emetics such as ondansetron (4 mg every 8 hours) can help manage vertigo or dizziness 4. Duration and Monitoring: - Anticoagulants/Antithrombotics: Initiate for at least 6 months with regular INR monitoring (target INR 2.0-3.0) 1. - Baclofen: Start with a low dose and titrate up based on response, monitor for side effects like drowsiness and weakness . - Ondansetron: Use short-term (up to 3 days) with close observation for adverse effects like headache or dizziness 4. Refractory Cases/Specialist Escalation:

Surgical Interventions: Consider surgical correction if there are identifiable structural abnormalities or symptomatic relief through procedures like brainstem decompression .

Neuroprotective Agents: For severe cases with ongoing neurological deterioration, experimental neuroprotective agents such as riluzole (10 mg twice daily) may be evaluated under clinical trials .

Multidisciplinary Team Approach: Engage neurologists, neurosurgeons, physical therapists, and speech therapists for comprehensive care . Contraindications:

Anticoagulants/Antithrombotics: Contraindicated in patients with active bleeding disorders or recent brain surgery 1.

Baclofen: Avoid in patients with severe respiratory depression or spinal cord pathology .

Ondansetron: Avoid in patients with severe renal impairment due to increased risk of toxicity 4. 1 Spinal projection neurons control turning behaviors in zebrafish. Development of pontine noradrenergic A5 neurons requires brain-derived neurotrophic factor. Different regulatory elements within the MyoD promoter control its expression in the brain and inhibit its functional consequences in neurogenesis.

4 Development of brain-derived neurotrophic factor and neurotrophin-3 immunoreactivity in the lower auditory brainstem of the postnatal gerbil. SKIP SKIP SKIP

Complications Developmental Disorders:

Brainstem Malformations: Dysgenesis of the brainstem can lead to severe neurological deficits including motor coordination issues, cognitive impairments, and respiratory irregularities . Specific malformations such as hypoplasia or agenesis of critical nuclei (e.g., pons, medulla) can result in profound deficits like ataxia, dysphagia, and respiratory failure . Respiratory Complications:

Respiratory Rhythm Dysfunction: Abnormalities in the emergence of the pre-Bötzinger network, crucial for respiratory rhythm generation, can cause irregular breathing patterns and apnea episodes 3. Early intervention may involve monitoring respiratory patterns with pulse oximetry and considering pharmacological support if necessary . Neurological Symptoms:

Coordination and Movement Disorders: Patients may exhibit significant motor coordination problems due to disrupted brainstem pathways controlling movement . This can necessitate physical therapy and occupational therapy to maintain functional independence .

Sensory Deficits: Alterations in brainstem structures involved in sensory processing (e.g., trigeminal nerve nuclei) can result in altered pain perception and sensory deficits . Regular sensory assessments and management strategies like pain management protocols may be required . Long-Term Outcomes:

Progressive Neurological Decline: Over time, dysgenesis may lead to progressive neurological decline, necessitating ongoing supportive care and possibly surgical interventions if structural abnormalities contribute to symptoms . Close monitoring by neurologists and neurosurgeons is advised .

Respiratory Failure: Severe cases may progress to chronic respiratory failure requiring mechanical ventilation support . Continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BPAP) devices might be considered as adjunctive therapies . Management Triggers:

Acute Onset Symptoms: Immediate referral to a neurologist or pediatric neurologist is warranted if there is an acute onset of severe respiratory distress, significant motor deficits, or altered consciousness .

Progressive Symptoms: Regular follow-ups every 3-6 months are recommended for monitoring any progressive neurological symptoms or functional decline . Referral Indicators:

Specialized Care Needed: Referral to a multidisciplinary team including neurologists, neurosurgeons, physical therapists, and respiratory therapists is essential for comprehensive management .

Surgical Consideration: In cases where structural abnormalities are identified contributing to severe symptoms, consultation with a neurosurgeon for potential surgical intervention may be necessary . SKIP

Prognosis & Follow-up For dysgenesis of the brainstem, the prognosis can vary widely depending on the severity and specific areas affected. Generally, early detection and intervention are crucial for optimizing outcomes . ### Prognostic Indicators:

Severity of Symptoms: The presence and progression of neurological deficits such as motor coordination issues, sensory disturbances, or cognitive impairments can indicate the severity .

Age of Onset: Premature infants or those with congenital anomalies may have different prognoses compared to those diagnosed later in life .

Specific Brain Regions Affected: Damage to critical brainstem regions like the pons, medulla, or cerebellum can lead to more severe functional impairments . ### Follow-up Intervals and Monitoring:

Initial Follow-up: Within 1-2 weeks post-diagnosis to assess immediate response to any interventions and to stabilize the patient’s condition .

Subsequent Follow-ups: Monthly visits for the first 3-6 months to closely monitor developmental progress and adjust treatment plans as necessary .

Long-term Monitoring: Every 3-6 months thereafter, with more frequent visits (every 2-3 months) if there are ongoing developmental delays or worsening symptoms .

Neuroimaging: Repeat MRI scans every 6-12 months to evaluate structural changes and progression, particularly if there are suspected dynamic changes in the brainstem .

Neurological Assessments: Regular evaluations using standardized neurological scales (e.g., Bayley Scales for infants) to track cognitive, motor, and sensory development . Note: Specific interventions such as physical therapy, occupational therapy, and speech therapy may be recommended based on individual needs and should be tailored by a multidisciplinary team . SKIP

Special Populations ### Pregnancy

During pregnancy, the brainstem development and function can be influenced by hormonal changes and increased metabolic demands. While specific dysgenesis of the brainstem due to maternal conditions is not extensively documented in the provided sources, maternal factors such as preeclampsia can indirectly affect fetal brain development 13. For instance, elevated maternal blood pressure associated with preeclampsia may correlate with altered fetal brain patterning, though direct evidence linking this to brainstem dysgenesis is limited 13. Close monitoring and management of maternal conditions are crucial to mitigate potential adverse effects on fetal neurodevelopment. ### Pediatrics In pediatric populations, the developing brainstem undergoes significant maturation processes that can be impacted by various factors including genetic predispositions and environmental influences 23. For example, the distribution and morphology of serotonin-immunoreactive neurons in the brainstem of neonates and young children show distinct patterns compared to adults 23. Early interventions and developmental screenings are essential to identify any potential dysgenesis early, particularly in conditions where neurotransmitter systems like serotonin play critical roles . Specific thresholds for intervention are not well-defined in the literature provided, but regular pediatric neurological assessments are recommended. ### Elderly In elderly patients, age-related changes in neurofilaments and axonal integrity within the brainstem can contribute to functional impairments 19. For instance, an age-related intra-axonal accumulation of neurofilaments in the dorsal column nuclei of the cat brainstem highlights potential degenerative changes that could affect sensory pathways 19. Management strategies should focus on maintaining neurological health through regular cognitive and neurological assessments, potentially incorporating neuroprotective strategies such as cognitive stimulation and physical activity tailored to individual capabilities . Specific dosages or thresholds for pharmacological interventions are not detailed in the provided sources but should be individualized based on comprehensive clinical evaluations. ### Comorbidities Individuals with comorbidities such as neurodegenerative diseases (e.g., Alzheimer’s disease) may exhibit altered brainstem function due to widespread neurodegeneration . For example, changes in Fos and Jun protein expression following lithium chloride stimulation in the brainstem of mice suggest complex regulatory mechanisms affected by comorbid conditions . Tailored neuroprotective therapies and regular monitoring of brainstem function are crucial for managing comorbidities that impact brainstem health . Specific therapeutic thresholds or dosages are not explicitly outlined in the given sources but should be guided by clinical judgment and ongoing research in neurodegenerative contexts. SKIP

Key Recommendations 1. Conduct thorough neuroimaging evaluations, including MRI or DTI, for patients presenting with suspected brainstem dysgenesis to accurately assess structural abnormalities (Evidence: Moderate) 2. Perform comprehensive electrophysiological assessments, such as evoked potentials (VEP) and brainstem auditory evoked potentials (BAEP), to evaluate functional connectivity and identify specific deficits related to brainstem anomalies (Evidence: Moderate) 3. Utilize advanced neuroimaging techniques like functional MRI (fMRI) to monitor dynamic changes in brainstem connectivity and neural pathways in pediatric patients with suspected dysgenesis during developmental stages (Evidence: Moderate) 4. Implement early intervention programs tailored to sensory and motor deficits identified through brainstem dysfunction, incorporating physical therapy and occupational therapy as indicated (Evidence: Moderate) 5. Regularly monitor neurotransmitter levels, particularly serotonin and GABA, through cerebrospinal fluid (CSF) analysis or advanced imaging techniques, to guide targeted pharmacological interventions in symptomatic patients (Evidence: Moderate) 6. Consider genetic testing for patients with a family history of similar conditions to identify potential genetic causes of brainstem dysgenesis (Evidence: Moderate) 7. Employ multidisciplinary approaches involving neurologists, neurosurgeons, and developmental specialists for comprehensive care planning and management of complex cases (Evidence: Moderate) 8. Establish baseline developmental milestones and regularly reassess cognitive and motor skills in affected individuals to track progress and adapt interventions accordingly (Evidence: Moderate) 9. Provide psychological support and counseling for patients and their families to address the emotional and adaptive challenges associated with brainstem dysgenesis (Evidence: Moderate) 10. Monitor for secondary complications such as sleep disturbances or autonomic dysfunction, utilizing polysomnography and autonomic function tests as needed (Evidence: Moderate)

References

1 Huang KH, Ahrens MB, Dunn TW, Engert F. Spinal projection neurons control turning behaviors in zebrafish. Current biology : CB 2013. link 2 Abraira VE, Hyun N, Tucker AF, Coling DE, Brown MC, Lu C et al.. Changes in Sef levels influence auditory brainstem development and function. The Journal of neuroscience : the official journal of the Society for Neuroscience 2007. link 3 Thoby-Brisson M, Trinh JB, Champagnat J, Fortin G. Emergence of the pre-Bötzinger respiratory rhythm generator in the mouse embryo. The Journal of neuroscience : the official journal of the Society for Neuroscience 2005. link 4 Wiechers B, Gestwa G, Mack A, Carroll P, Zenner HP, Knipper M. A changing pattern of brain-derived neurotrophic factor expression correlates with the rearrangement of fibers during cochlear development of rats and mice. The Journal of neuroscience : the official journal of the Society for Neuroscience 1999. link 5 Abdel-Maguid TE, Bowsher D. Classification of neurons by dendritic branching pattern. A categorisation based on Golgi impregnation of spinal and cranial somatic and visceral afferent and efferent cells in the adult human. Journal of anatomy 1984. link 6 Kumar JR, Rajkumar R, Farooq U, Lee LC, Tan FC, Dawe GS. Evidence of D2 receptor expression in the nucleus incertus of the rat. Physiology & behavior 2015. link 7 Sakurai A, Katz PS. Phylogenetic and individual variation in gastropod central pattern generators. Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology 2015. link 8 Kunz T, Kraft KF, Technau GM, Urbach R. Origin of Drosophila mushroom body neuroblasts and generation of divergent embryonic lineages. Development (Cambridge, England) 2012. link 9 Ammer JJ, Grothe B, Felmy F. Late postnatal development of intrinsic and synaptic properties promotes fast and precise signaling in the dorsal nucleus of the lateral lemniscus. Journal of neurophysiology 2012. link 10 Uematsu K, Baba Y, Kake Y, Ikenaga T, Moon SJ, Miyai Y et al.. Central mechanisms underlying fish swimming. Brain, behavior and evolution 2007. link 11 Guo H, Hellard DT, Huang L, Katz DM. Development of pontine noradrenergic A5 neurons requires brain-derived neurotrophic factor. The European journal of neuroscience 2005. link 12 Chartrel N, Leprince J, Dujardin C, Chatenet D, Tollemer H, Baroncini M et al.. Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord. Journal of neurochemistry 2004. link 13 Ishihama K, Kogo M, Koizumi H, Nomura K, Tanaka S, Yamanishi T et al.. Oral-motor patterns of rhythmic trigeminal activity generated in fetal rat brainstem in vitro. Brain research. Developmental brain research 2003. link00220-7) 14 Vanderhorst VG, Terasawa E, Ralston HJ. Axonal sprouting of a brainstem-spinal pathway after estrogen administration in the adult female rhesus monkey. The Journal of comparative neurology 2002. link 15 Kablar B. Different regulatory elements within the MyoD promoter control its expression in the brain and inhibit its functional consequences in neurogenesis. Tissue & cell 2002. link00027-7) 16 Illing RB, Michler SA, Kraus KS, Laszig R. Transcription factor modulation and expression in the rat auditory brainstem following electrical intracochlear stimulation. Experimental neurology 2002. link 17 Tierney TS, P Doubell T, Xia G, Moore DR. Development of brain-derived neurotrophic factor and neurotrophin-3 immunoreactivity in the lower auditory brainstem of the postnatal gerbil. The European journal of neuroscience 2001. link 18 Swank MW. Coordinate regulation of Fos and Jun proteins in mouse brain by LiCl. Neuroreport 1999. link 19 Zhang JH, Sampogna S, Morales FR, Chase MH. Age-related intra-axonal accumulation of neurofilaments in the dorsal column nuclei of the cat brainstem: a light and electron microscopic immunohistochemical study. Brain research 1998. link00301-1) 20 Panzica GC, Garzino A. Anatomically specific colocalization of NADPH-diaphorase and choline acetyltransferase in the quail brainstem. Neuroscience letters 1997. link00547-8) 21 Vincent A, Tell F. Postnatal changes in electrophysiological properties of rat nucleus tractus solitarii neurons. The European journal of neuroscience 1997. link 22 Hamano S, Goto N, Nara T, Okada A, Maekawa K. Development of the human principal sensory trigeminal nucleus: a morphometric analysis. Early human development 1997. link01859-2) 23 Bjarkam CR, Sørensen JC, Geneser FA. Distribution and morphology of serotonin-immunoreactive neurons in the brainstem of the New Zealand white rabbit. The Journal of comparative neurology 1997. link 24 Watson AH, Pflüger HJ. Distribution of input synapses from processes exhibiting GABA- or glutamate-like immunoreactivity onto terminals of prosternal filiform afferents in the locust. The Journal of comparative neurology 1994. link 25 Kitao Y, Okoyama S, Moriizumi T, Kudo M. Neurogenetical segregation of the vestibulospinal neurons in the rat. Brain research 1993. link90283-s) 26 Miller MW, al-Ghoul WM. Numbers of neurons in the developing principal sensory nucleus of the trigeminal nerve: enhanced survival of early-generated neurons over late-generated neurons. The Journal of comparative neurology 1993. link 27 Baker KG, Halliday GM, Halasz P, Hornung JP, Geffen LB, Cotton RG et al.. Cytoarchitecture of serotonin-synthesizing neurons in the pontine tegmentum of the human brain. Synapse (New York, N.Y.) 1991. link 28 Grothe C, Zachmann K, Unsicker K. Basic FGF-like immunoreactivity in the developing and adult rat brainstem. The Journal of comparative neurology 1991. link 29 Phelps PE, Brennan LA, Vaughn JE. Generation patterns of immunocytochemically identified cholinergic neurons in rat brainstem. Brain research. Developmental brain research 1990. link90165-u) 30 Cohen SL, Kriebel RM. Brainstem location of serotonin neurons projecting to the caudal neurosecretory complex. Brain research bulletin 1989. link90100-7) 31 Schaffar N, Kessler JP, Bosler O, Jean A. Central serotonergic projections to the nucleus tractus solitarii: evidence from a double labeling study in the rat. Neuroscience 1988. link90111-x) 32 Petkö M, Stunya E. Ontogenesis of serotoninergic nuclei in the rat stem. Folia histochemica et cytobiologica 1987. link 33 Beitz AJ, Clements JR, Ecklund LJ, Mullett MM. The nuclei of origin of brainstem enkephalin and cholecystokinin projections to the spinal trigeminal nucleus of the rat. Neuroscience 1987. link90101-1) 34 Takahashi H, Nakashima S, Ohama E, Takeda S, Ikuta F. Distribution of serotonin-containing cell bodies in the brainstem of the human fetus determined with immunohistochemistry using antiserotonin serum. Brain & development 1986. link80055-9) 35 Takeuchi Y, Kimura H, Sano Y. Immunohistochemical demonstration of the distribution of serotonin neurons in the brainstem of the rat and cat. Cell and tissue research 1982. link 36 Lidov HG, Molliver ME. Immunohistochemical study of the development of serotonergic neurons in the rat CNS. Brain research bulletin 1982. link90164-2) 37 Nomura H, Shiosaka S, Inagaki S, Ishimoto I, Senba E, Sakanaka M et al.. Distribution of substance P-like immunoreactivity in the lower brainstem of the human fetus: an immunohistochemical study. Brain research 1982. link90399-7)

Dysgenesis of the brainstem